As of 2025-07-16, the Fair Value of Provectus Biopharmaceuticals Inc (PVCT) is -0.06 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 0.07 USD, the upside of Provectus Biopharmaceuticals Inc is -187.31%.
With the market price of 0.07 USD and our fair value calculation, Provectus Biopharmaceuticals Inc (PVCT) is not a good investment. Investing in PVCT stocks now will result in a potential loss of 187.31%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -6.68 | -5.54 | -3.55 | -3.10 | -4.73 | -4.72 |
| YoY growth | 3.47% | 17.07% | 35.92% | 12.63% | -52.58% | 3.30% |
| Market Cap (mil) | 30.74 |
| P/E | |
| Forward P/E |
| EPS | -0.01 |
| Avg earnings growth rate | 3.30% |
| TTM earnings | -5.37 |